Skip to main content

Table 2 Adjusted risk for secondary outcomes for subjects treated with 4 g/acetaminiophen/day

From: A randomized, placebo-controlled trial to determine the course of aminotransferase elevation during prolonged acetaminophen administration

  Extended dosing ALT increase > 10 IU/L ALT increase >50% above baseline
Variable Odds ratio 95% Confidence interval Odds ratio 95% Confidence interval Odds ratio 95% Confidence interval
Female (vs Male) 1.47 0.64 to 3.73 1.03 0.53 to 2.03 1.21 0.61 to 2.39
Race       
 Caucasian 1.0 Ref 1.0 Ref 1.0 Ref
 Black 1.71 0.47 to 6.26 3.56 1.02 to 12.45 1.80 0.54 to 5.99
 Hispanic 1.86 0.79 to 4.40 1.45 0.66 to 3.2 1.67 0.75 to 3.69
 Other 1.85 0.58 to 5.91 1.40 0.50 to 3.96 1.81 0.63 to 5.24
Age (per yr) 1.01 0.98 to 1.04 1.02 0.99 to 1.04 1.02 1.00 to 1.05
Baseline ALT (Per IU/L) 1.03 0.98 to 1.08 1.01 0.97 to 1.05 0.96 0.92 to1.00
BMI 0.98 0.93 to 1.04 0.98 0.93 to 1.03 0.99 0.94 to 1.04
No ethanol use 1.81 0.81 to 4.1 0.90 0.42 to 1.92 0.89 0.42 to 1.88